Close Menu

Galena Biopharma

NEW YORK (GenomeWeb News) – Galena Biopharma and Leica Biosystems today announced a deal for the development of a companion diagnostic for Galena's therapeutic for breast cancer.

With Marina Biotech's back against the wall, the RNAi drugs field may soon see the departure of its third player this year, following the bankruptcy of Traversa Therapeutics and the acquisition of Tacere Therapeutics by Benitec Biopharma.

RXi Pharmaceuticals this week released its second-quarter financial results, posting a surge in losses tied to its spinout from former parent firm Galena Biopharma (GSN

Galena Biopharma, the former parent firm of RXi Pharmaceuticals, has settled four lawsuits filed by investor groups that had raised questions about its now-completed spinout of the RNAi drug developer.

Galena Biopharma late last month completed its spinout of RNAi drugs subsidiary RXi Pharmaceuticals, ending a year-long saga that included an acquisition, litigation, and a management shakeup that included the loss of RXi's CSO.

Galena Biopharma said this week that it has taken the “final steps” to complete its planned spinout of RNAi subsidiary RXi Pharmaceuticals.

Galena Biopharma this week said that it has taken steps to end a dispute with investors that threatened to block the company's planned spinout of RNAi subsidiary RXi Pharmaceuticals.

Pages

Wired reports on how genetic genealogy's use in forensics has exploded in the year since an arrest in the Golden State Killer case was made.

Retraction Watch reports that the increase in retracted papers at a journal is due to more resources there to tackle publication ethics.

New York City has settled with a forensic scientist who was fired after questioning a DNA testing approach used by the medical examiner's office, the New York Times reports.

In Nature this week: technique for measuring replication fork movement, WINTHER trial results, and more.